Karyopharm Therapeutics Inc (KPTI) — Cash Flow Reinvestment Rate

Latest as of December 2021: 1.20x

Karyopharm Therapeutics Inc (KPTI) has a Cash Flow Reinvestment Rate of 1.20x as of December 2021, reinvesting $30.68 Million (capex $207.00K plus investments $30.48 Million) from operating cash flow of $25.48 Million. Explore KPTI capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

1.20x
(Capex + Investments) / Operating CF

Total Reinvested

$30.68 Million
Capex + Investments

Operating Cash Flow

$25.48 Million
USD

Capital Expenditures

$207.00K
USD

Annual Cash Flow Reinvestment Rate for Karyopharm Therapeutics Inc (None–None)

Year-by-year capital reinvestment analysis for Karyopharm Therapeutics Inc. For live market cap and broader valuation context, see market value of Karyopharm Therapeutics Inc.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow